Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Weighted Average) (2016 - 2025)

United Therapeutics' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $44.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 1.99% year-over-year to $44.3 million; the TTM value through Dec 2025 reached $44.3 million, down 1.99%, while the annual FY2025 figure was $44.3 million, 1.99% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $44.3 million at United Therapeutics, up from $43.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $47.0 million in Q1 2024 and bottomed at $43.8 million in Q3 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $45.2 million (2022), against an average of $45.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) rose 3.53% in 2023 before it dropped 4.72% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $44.9 million in 2021, then grew by 1.34% to $45.5 million in 2022, then rose by 2.86% to $46.8 million in 2023, then decreased by 3.42% to $45.2 million in 2024, then dropped by 1.99% to $44.3 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Shares Outstanding (Weighted Average) are $44.3 million (Q4 2025), $43.8 million (Q3 2025), and $45.1 million (Q2 2025).